Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1019290

registered interest
date	03/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 November (HL10893), what is the average cost to the NHS of treating patients with (1) leukaemia, (2) non-hodgkin lymphoma, (3) hodgkin lymphoma, and (4) myeloma.
tabling member printed	Lord Mendelsohn
uin	HL11979
answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>The data is not collected in the format requested.</p> answering member printed Lord O'Shaughnessy question first answered 13/12/2018 15:17:35 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

1005631

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the level of spending on treatment for and research into blood cancer in other countries compared to the UK.
tabling member printed	Lord Mendelsohn
uin	HL11402
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>NHS England does not hold information on the level of spending on blood cancer treatment in other countries.</p> answering member printed Lord O'Shaughnessy question first answered 26/11/2018 13:00:38 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

1005632

registered interest
date	12/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Expenditure
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 November (HL10893), what data they hold on on the amount spent by the NHS on (1) treatment, and (2) drugs for different health conditions.
tabling member printed	Lord Mendelsohn
uin	HL11403
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>The information is not collected centrally in the format requested.</p><p>NHS Improvement collect and publish reference costs data which are the average unit cost to the National Health Service of providing defined services to NHS patients in England in a given financial year rather than the total amount spent on treatment.</p><p>As a subset of these reference costs, data is collected about high cost drugs only.</p> answering member printed Lord O'Shaughnessy question first answered 26/11/2018 13:01:30 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

993365

registered interest
date	22/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government (1) how many drugs were available on the NHS for the treatment of blood cancer, and (2) how much the NHS spent on blood cancer drugs, in each of the past five years.
tabling member printed	Lord Mendelsohn
uin	HL10893
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>NHS England has advised that it is not possible to provide a comprehensive list of drugs that are available specifically for blood cancer or how much the National Health Service spends on blood cancer drugs as cancer drugs are often licenced for multiple different types of cancer.</p> answering member printed Lord O'Shaughnessy question first answered 05/11/2018 14:29:39 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

993366

registered interest
date	22/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what is the current level of spending by the NHS on blood cancer treatment; and what estimate they have made of the proportion of the NHS budget that will be spent on blood cancer treatments in each of the next five years.
tabling member printed	Lord Mendelsohn
uin	HL10894
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>NHS England is unable to provide current or previous spend on drugs specifically for blood cancer as many of these drugs have multiple indications. For the same reason it is not possible to estimate future spend.</p> answering member printed Lord O'Shaughnessy question first answered 05/11/2018 13:36:52 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

993367

registered interest
date	22/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to consult on proposals to incorporate input from NHS England into the NICE technology appraisal process when determining treatment criteria.
tabling member printed	Lord Mendelsohn
uin	HL10895
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for determining the processes it uses in the development of its guidance.</p><p>NICE has advised that it has no plans to consult on changes to its processes as it has been able to use its existing structures to ensure NHS England’s intended commissioning criteria are included within the appraisal process. NICE’s existing technology appraisal process that was updated in April 2018 already allows input from NHS England at various points.</p><p>Patient groups that are registered stakeholders participating in each technology appraisal will be able to provide their views on NHS England’s proposed commissioning criteria as part of the technical engagement step. Where applicable, all patient groups and individual patients have the opportunity to comment during consultation on an appraisal consultation document.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL10896 question first answered 05/11/2018 15:13:35 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

993368

registered interest
date	22/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to ensure patient groups contribute to the development of treatment criteria for NICE approved treatments in the future.
tabling member printed	Lord Mendelsohn
uin	HL10896
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for determining the processes it uses in the development of its guidance.</p><p>NICE has advised that it has no plans to consult on changes to its processes as it has been able to use its existing structures to ensure NHS England’s intended commissioning criteria are included within the appraisal process. NICE’s existing technology appraisal process that was updated in April 2018 already allows input from NHS England at various points.</p><p>Patient groups that are registered stakeholders participating in each technology appraisal will be able to provide their views on NHS England’s proposed commissioning criteria as part of the technical engagement step. Where applicable, all patient groups and individual patients have the opportunity to comment during consultation on an appraisal consultation document.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL10895 question first answered 05/11/2018 15:13:35 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

940088

registered interest
date	12/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Reference Groups
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 26 June (HL8565), whether they will publish a list of meeting dates and participants for each Clinical Reference Group since 2016.
tabling member printed	Lord Mendelsohn
uin	HL9503
answer	answer is ministerial correction date of answer 23/07/2018 answer text <p>There are five Clinical Reference Groups (CRGs) which fall under the Cancer Programme of Care Board. CRGs provide clinical advice and leadership on the specialised services in cancer. These groups of clinicians, commissioners, public health experts, patients and carers use their specific knowledge and expertise to advise NHS England on the best ways that specialised services should be provided.</p><p>A list of the participants and meeting dates is attached, due to the size of the data.</p> answering member printed Lord O'Shaughnessy question first answered 23/07/2018 13:49:11 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Annex to HL9503 formatted.docx title Participants and meeting dates CRGs
tabling member	4286 label Biography information for Lord Mendelsohn

940089

registered interest
date	12/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 26 June (HL8564), whether they will publish details of NHS England's process for developing treatment criteria.
tabling member printed	Lord Mendelsohn
uin	HL9504
answer	answer is ministerial correction date of answer 25/07/2018 answer text <p><strong></strong>NHS England has advised us that with regard to its process for developing treatment criteria, it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>Furthermore, NICE and NHS England are working closely to ensure that the process for translating NICE recommendations into clinical commissioning criteria is fully aligned. This collaboration will ensure the steps for the setting of treatment criteria are fully integrated into the process NICE follows when developing its guidance. This process will include consideration of the evidence submitted to NICE, advice from NHS England, and consideration of how any potential recommendations will be implemented. These draft treatment criteria will then be subject to stakeholder consultation as part of the NICE process and updated, as appropriate, in light of feedback received. Once this process has been fully finalised with NICE, full details will be published.</p> answering member printed Lord O'Shaughnessy question first answered 25/07/2018 11:06:11 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn

940090

registered interest
date	12/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 26 June (HL8563), whether they will consider conducting an analysis of the number of Individual Funding Requests submitted to the NHS for the treatment of blood cancer.
tabling member printed	Lord Mendelsohn
uin	HL9505
answer	answer is ministerial correction date of answer 23/07/2018 answer text <p>NHS England is responsible for its processes for considering Individual Funding Requests. NHS England has advised that during 2017/18, 1,193 Individual Funding Requests were considered by NHS England and that an analysis of how may related to treatments for blood cancer has not been conducted. Each individual case would have to be reviewed in order to identify which related a blood cancer and NHS England has no plans to carry out such an analysis.</p> answering member printed Lord O'Shaughnessy question first answered 23/07/2018 12:55:56 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4286 label Biography information for Lord Mendelsohn